ClinicalTrials.gg
Not yet recruitingNCT07852962Updated Oct 1, 2026

Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in Healthy Chinese Participants.

A Phase 1 interventional study of BMS-986446 and Placebo in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to assess the drug levels, immune response, safety and tolerability of BMS-986446 in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pharmacokinetics
  • PK
  • BMS-986446
  • Healthy Chinese Participants
  • IV administration
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be of Chinese ethnicity (both biological parents are ethnically Chinese).
  • Participants must be Healthy adult male and female (as assigned at birth and non-pregnant and non-nursing).
  • Participants must have of 18.0 to 28.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have general history of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated, or hematological disorder; allergic disease; metabolic disorder; cancer; or cirrhosis.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    BMS-986446

    Drug: BMS-986446

  • Experimental
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: PRX005, Moponetug

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to Day 85

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 85

  3. Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to Day 85

  4. Geometric mean ratios of area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]

    Time frame: Up to Day 85

  5. Total body clearance in intravenous infusion (CLT)

    Time frame: Up to Day 85

  6. Volume of distribution of terminal phase in intravenous administration (Vz)

    Time frame: Up to Day 85

  7. Apparent terminal serum half-life [T-HALF]

    Time frame: Up to Day 85

Secondary outcomes

  1. Number of participants with anti-drug antibody (ADA) formation

    Time frame: Up to Day 85

  2. Number of participants with adverse events (AEs)

    Time frame: Up to approximately 85 days

  3. Number of participants with vital sign abnormalities

    Time frame: Up to approximately 85 days

  4. Number of participants with 12-lead electrocardiogram (12-lead-ECG) abnormalities

    Time frame: Up to approximately 85 days

  5. Number of participants with physical examination abnormalities

    Time frame: Up to approximately 85 days

  6. Number of participants with body weight abnormalities

    Time frame: Up to approximately 85 days

  7. Number of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 85 days

  8. Number of Participants with Treatment Emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately 85 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2027; primary completion for Jul 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 1, 2026
StartEst.
Feb 10, 2027
Primary completionEst.
Jul 18, 2027
CompletionEst.
Jul 18, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852962
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Feb 10, 2027 (estimated)
Primary completion
Jul 18, 2027 (estimated)
Completion
Jul 18, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Moponetug

Start the discussion